Nebivolol: A third-generation β-blocker for hypertension

Clinical Therapeutics

Volumn 31, Issue 3, 2009, Pages 447-462

  Cheng, Judy W M ^a,b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

blockers; heart failure; hypertension; nebivolol

Indexed keywords

AMFEBUTAMONE; AMIODARONE; AMLODIPINE; ATENOLOL; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CELECOXIB; CHLORPHENIRAMINE; CHLORPROMAZINE; CITALOPRAM; COCAINE; DESIPRAMINE; DIPHENHYDRAMINE; DOXEPIN; DOXORUBICIN; ENALAPRIL; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LISINOPRIL; METHADONE; METOPROLOL; NEBIVOLOL; NIFEDIPINE; PAROXETINE; PLACEBO; TELMISARTAN; UNINDEXED DRUG;

ARTHRITIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BACKACHE; BLOOD PRESSURE REGULATION; BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FATIGUE; FLUSHING; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; HYPESTHESIA; HYPOTENSION; INSOMNIA; INTERMITTENT CLAUDICATION; KIDNEY FAILURE; LIBIDO; LIVER FUNCTION; LUNG EDEMA; MIGRAINE; MORTALITY; MYALGIA; NAUSEA; PARESTHESIA; PERIPHERAL EDEMA; PROPHYLAXIS; PRURITUS; PSORIASIS; RAYNAUD PHENOMENON; RHINITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH DISEASE; SYNCOPE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INTERACTIONS; ETHANOLAMINES; HEART FAILURE; HUMANS; HYPERTENSION; RECEPTORS, ADRENERGIC, BETA-1; TREATMENT OUTCOME;

EID: 64849101326     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.03.007     Document Type: Article

References (62)

1. Rosamond W., Flegal K., Friday G., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2007;115:e172]. Circulation 115 (2007) e69-e171
2. US Dept of Health and Human Services. The Seventh Reportof the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf Accessed April 10, 2007
3. Wiysonge C.S., Bradley H., Mayosi B.M., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev (2007) CD002003
4. Ubel P.A., Jepson C., and Asch D.A. Misperceptions about betablockers and diuretics: A national survey of primary care physicians. J Gen Intern Med 18 (2003) 977-983
5. Westfall T.C., and Westfall D.P. Adrenergic agonists and antagonists. In: Brunton L.L. (Ed). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th Edition (2006), McGraw-Hill, New York, NY 137-181
6. Gress T.W., Nieto F.J., Shahar E., et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342 (2000) 905-912
7. Carlberg B., Samuelsson O., and Lindholm L.H. Atenolol in hypertension: Is it a wise choice [published correction appears in Lancet. 2005;365:656]?. Lancet 364 (2004) 1684-1689
8. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
9. Dahlöf B., Sever P.S., Poulter N.R., et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicenter randomized controlled trial. Lancet 366 (2005) 895-906
10. Khan N.A., Hemmelgarn B., Herman R.J., et al., Canadian Hypertension Education Program. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2-therapy. Can J Cardiol 24 (2008) 465-475
11. Mancia G., De Backer G., Dominiczak A., et al., Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28 (2007) 1462-1536
12. Bangalore S., Messerli F.H., Kostis J.B., and Pepine C.J. Cardiovascular protection using beta-blockers: A critical review of the evidence. J Am Coll Cardiol 50 (2007) 563-572
13. Veverka A., Nuzum S.D., and Jolly J.L. Nebivolol: A third-generation beta-adrenergic blocker. Ann Pharmacother 40 (2006) 1353-1360
14. Beevers G., Lip G.Y., and O'Brien E. ABC of hypertension: The pathophysiology of hypertension. BMJ 322 (2001) 912-916
15. Grassi G. Adrenergic overdrive as the link among hypertension, obesity, and impaired thermogenesis: Lights and shadows. Hypertension 49 (2007) 5-6
16. Goldstein D.S. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 5 (1983) 86-99
17. Anderson E.A., Sinkey C.A., Lawton W.J., and Mark A.L. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 14 (1989) 177-183
18. Grassi G., Cattaneo B.M., Seravalle G., et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 31 (1998) 68-72
19. Grassi G., and Mancia G. Neurogenic hypertension: Is the enigma of its origin near the solution?. Hypertension 43 (2004) 154-155
20. Egan B.M., Basile J., Chilton R.J., and Cohen J.D. Cardioprotection: The role of beta-blocker therapy. J Clin Hypertens (Greenwich) 7 (2005) 409-416
21. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
22. Cohen J.D. Overview of physiology, vascular biology, and mechanisms of hypertension. J Manag Care Pharm 13 Suppl (2007) S6-S8
23. Mangrella M., Rossi F., Fici F., and Rossi F. Pharmacology of nebivolol. Pharmacol Res 38 (1998) 419-431
24. Nebivolol (Bystolic™) prescribing information. http://www.regencerx.com/docs/physicianRx/bystolic0608.pdf Accessed March 3, 2009
25. Brixius K., Bundkirchen A., Bölck B., et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 133 (2001) 1330-1338
26. Tzemos N., Lim P.O., and MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension: A randomized double-blind crossover study. Circulation 104 (2001) 511-514
27. Peter P., Martin U., Sharma A., and Dunne F. Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetes with mild to moderate hypertension. J Clin Pharm Ther 31 (2006) 153-159
28. Troost R., Schwedhelm E., Rojczyk S., et al. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 50 (2000) 377-379
29. Poirier L., Cléroux J., Nadeau A., and Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19 (2001) 1429-1435
30. Fogari R., Zoppi A., Lazzari P., et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 11 (1997) 753-757
31. Celik T., Yuksel U.C., Iyisoy A., et al. Effects of nebivolol on platelet activation in hypertensive patients: A comparative study with metoprolol. Int J Cardiol 116 (2007) 206-211
32. Lefebvre J., Poirier L., Poirier P., et al. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol 63 (2006) 575-582
33. Prisant L.M. Nebivolol: Pharmacologic profile of an ultraselective, vasodilatory beta-1 blocker. J Clin Pharmacol 48 (2008) 225-239
34. Cheymol G., Woestenborghs R., Snoeck E., et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 51 (1997) 493-498
35. Van Nueten L., and De Crée J. Nebivolol: Comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc Drugs Ther 12 (1998) 339-344
36. Flockhart D.A. Drug interactions: Cytochrome P450 drug interaction table. http://medicine.iupui.edu/flockhart/table.htm Accessed December 21, 2008
37. Kamali F., Howes A., Thomas S.H., et al. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol 43 (1997) 201-204
38. Van Nueten L., Dupont A.G., Vertommen C., et al. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 11 (1997) 139-144
39. Van Nueten L., Taylor F.R., and Robertson J.I. Nebivolol vs atenolol and placebo in essential hypertension: A doubleblind randomised trial. J Hum Hypertens 12 (1998) 135-140
40. Kamp O., Sieswerda G.T., and Visser C.A. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 92 (2003) 344-348
41. Grassi G., Trevano FQ Facchini A., et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: Results of a double-blind randomized multicentre trial. Blood Press Suppl 2 (2003) 35-40
42. Czuriga I., Riecansky I., Bodnar J., et al., NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: The Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther 17 (2003) 257-263
43. Lacourcière Y., Lefebvre J., Poirier L., et al. A double-blind crossover comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension. Am J Ther 1 (1994) 74-80
44. Rosei E.A., Rizzoni D., Comini S., Boari G., and Nebivolol-Lisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: A randomized multicenter doubleblind study. Blood Press Suppl 1 (2003) 30-35
45. Van Nueten L., Schelling A., Vertommen C., et al. Nebivolol vs enalapril in the treatment of essential hypertension: A double-blind randomised trial. J Hum Hypertens 11 (1997) 813-819
46. Fountoulaki K., Dimopoulos V., Giannakoulis J., et al. Left ventricular mass and mechanics in mild-to-moderate hypertension: Effect of nebivolol versus telmisartan. Am J Hypertens 18 (2005) 171-177
47. Van Nueten L., Lacourcière Y., Vyssoulis G., et al. Nebivolol versus nifedipine in the treatment of essential hypertension: A doubleblind, randomized, comparative trial. Am J Ther 5 (1998) 237-243
48. Mazza A., Gil-Extremera B., Maldonato A., et al. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press 11 (2002) 182-188
49. Cazzola M., Matera M.G., Ruggeri P., et al. Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration 71 (2004) 159-164
50. Papademetriou V. Comparison of nebivolol monotherapy versus nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. Am J Cardiol 103 (2009) 273-278
51. Flather M.D., Shibata M.C., Coats A.J., et al., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
52. Dobre D., van Veldhuisen D.J., Mordenti G., et al., SENIORS Investigators. Tolerability and doserelated effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 154 (2007) 109-115
53. Ghio S., Magrini G., Serio A., et al., SENIORS Investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: Results of the SENIORS echocardiographic substudy [published correction appears in Eur Heart J. 2006;27:1760]. Eur Heart J 27 (2006) 562-568
54. Patrianakos A.P., Parthenakis F.I., Mavrakis H.E., et al. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study. Am Heart J 150 (2005) 985
55. Evans R.W., Rizzoli P., Loder E., and Bana D. Beta-blockers for migraine. Headache 48 (2008) 455-460
56. Schellenberg R., Lichtenthal A., Wöhling H., et al. Nebivolol and metoprolol for treating migraine: An advance on beta-blocker treatment?. Headache 48 (2008) 118-125
57. Shabsigh R., Perelman M.A., Lockhart D.C., et al. Health issues of men: Prevalence and correlates of erectile dysfunction. J Urol 174 (2005) 662-667
58. Doumas M., Tsakiris A., Douma S., et al. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl 8 (2006) 177-182
59. Brixius K., Middeke M., Luchtenthal A., et al. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): Benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 34 (2007) 327-331
60. Drug prices and information. http://www.drugstore.com/pharmacy/drugindex/default.asp?trx=1Z5015 Accessed August 28, 2008
61. Gonzalez E.R. Pharmacoeconomic benefits of antihypertensive therapy. J Manag Care Pharm 13 Suppl (2007) S20-S21
62. Yao G., Freemantle N., Flather M., et al., SENIORS Investigators. Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: An individual patient-based simulation model. PharmacoEconomics 26 (2008) 879-889